• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by AnaptysBio Inc.

    1/6/26 9:02:48 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001239648
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ANAPTYSBIO, INC
    SEC File Number
    001-37985
    Address of Issuer
    10770 WATERIDGE CIRCLE, SUITE 210
    SAN DIEGO
    CALIFORNIA
    94005
    Phone
    858-362-6295
    Name of Person for Whose Account the Securities are To Be Sold
    ERIC J LOUMEAU
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    2983134085.852802336801/05/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common 01/05/2026Restricted Stock UnitsIssuerCheckbox not checked298301/05/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Eric J. Loumeau
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common12/22/202510000510000
    Eric J. Loumeau
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common12/18/20251416625.59
    Eric J. Loumeau
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common12/17/202510000460000
    Eric J. Loumeau
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common12/16/20258240238960

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/06/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Eric J Loumeau

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ANAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    1/7/2026$70.00Buy
    UBS
    10/13/2025$78.00Overweight
    Barclays
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on AnaptysBio with a new price target

    UBS resumed coverage of AnaptysBio with a rating of Buy and set a new price target of $70.00

    1/7/26 8:39:16 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AnaptysBio with a new price target

    Barclays initiated coverage of AnaptysBio with a rating of Overweight and set a new price target of $78.00

    10/13/25 8:51:16 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

    Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. ("Tesaro") regarding their Collaboration and Exclusive License Agreement ("Collaboration Agreement"), which entitles Anaptys to receive royalties upon sales of Jemperli. As previously disclosed, Anaptys approached Tesaro to engage in good faith

    1/8/26 6:00:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.   A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30 days following the event. About Anaptys Anaptys is a clinical-stage biotechnology company focused on deli

    1/6/26 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

    WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations. The BLA is supported by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies, wher

    12/15/25 7:00:00 AM ET
    $ANAB
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    SEC Filings

    View All

    SEC Form 144 filed by AnaptysBio Inc.

    144 - ANAPTYSBIO, INC (0001370053) (Subject)

    1/9/26 7:14:19 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AnaptysBio Inc.

    144 - ANAPTYSBIO, INC (0001370053) (Subject)

    1/9/26 7:12:59 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    1/9/26 5:17:16 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Lizzul Paul F. converted options into 8,525 shares and sold $163,192 worth of shares (3,650 units at $44.71), increasing direct ownership by 13% to 42,088 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/9/26 7:16:03 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Mulroy Dennis converted options into 6,700 shares and sold $112,446 worth of shares (2,515 units at $44.71), increasing direct ownership by 24% to 21,852 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/9/26 7:14:52 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Loumeau Eric J converted options into 5,888 shares and sold $98,809 worth of shares (2,210 units at $44.71), increasing direct ownership by 40% to 12,835 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/9/26 7:13:28 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/2/25 6:17:02 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    8/16/24 12:04:31 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Leadership Updates

    Live Leadership Updates

    View All

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

    After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

    9/18/23 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 4:00:05 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 9:24:47 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

    SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

    8/16/24 12:07:11 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Financials

    Live finance-specific insights

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

    Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

    5/11/23 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care